COVID-19: India Starts Massive Vaccine Rollout

COVID-19: India Starts Massive Vaccine Rollout

COVID-19: India Starts Massive Vaccine Rollout

India has on Saturday began one of the world’s biggest coronavirus vaccination programmes, hoping to end a pandemic that has killed 150,000 people in the country and attacked the economy.

Over the coming months, India aims to inoculate around a quarter of the population, or 300 million people. They include healthcare workers, people aged over 50 and those at high risk.

On the first day, around 300,000 people were set to be vaccinated at 3,000 centres. About 150,000 staff in 700 districts have been trained to administer jabs and keep records.

The government aims to manage the entire process digitally with its own app, CoWIN, which will link every vaccine dose to its recipient.

India has four “mega depots” to take delivery of the vaccines and transport them to state distribution hubs in temperature-controlled vans, keeping the doses colder than 8 degrees Celsius (46.4 Fahrenheit).

A total of 29,000 cold-chain points, 240 walk-in coolers, 70 walk-in freezers, 45,000 ice-lined refrigerators, 41,000 deep freezers and 300 solar fridges are at the ready.

These will be needed once the Indian summer arrives in the coming months.

In one recent practice run in a rural area, a consignment of dummy vaccines was photographed being delivered by bicycle.

To stop any of the vials from being stolen and being sold on India’s large drugs black market, authorities are taking no chances, with armed police guarding every truck.

CCTVs are in place at warehouses with entry subject to fingerprint authentication. Automated data loggers will monitor storage temperature and transfer messages every three seconds to a central unit, according to the Times of India.

Preeti Kumar, a public health specialist, told AFP;

Security measures are essential to not only address the issue of logistics and safety but also build confidence in people that the supply chain is intact, unbroken and safe to the point of delivery.

Meanwhile, India has ordered an initial 11 million doses of Covishield, AstraZeneca’s vaccine made by India’s Serum Institute, at 200 rupees ($2.74/N1,085) each, and 5.5 million doses of Covaxin at 206 rupees each ($2.82/N1,117).

The government’s “emergency approval” of Covaxin, made by India’s Bharat Biotech, has some doctors worried because phase 3 human trials are yet to be completed.

With Covaxin still in “clinical trial mode”, Indians being given the shot on Saturday were given a consent form to sign that made clear that its “clinical efficacy is yet to be established”.

Authorities say people will be given two doses of one of the vaccines — and not one of each — 28 days apart. Effectiveness begins 14 days after the second shot, they say.

Serum plans later to sell the jab privately to Indian individuals and firms for 1,000 rupees ($14/N5,546), raising fears that the rich will get inoculated sooner.

A recent survey of 18,000 people across India found that 69 percent were in no rush to get a COVID-19 shot, in part due to public scepticism fuelled by online disinformation.

Health Minister Harsh Vardhan took to social media on Thursday to dispel some of the doubts.

He tweeted;

There is no scientific evidence to suggest that #COVIDVaccine could cause infertility in either men or women. Kindly do not pay heed to such rumours or information from unverified sources.

Other developing countries are banking on India for getting vaccines, and Brazil wanted to send a plane to India this weekend to collect two million doses from Serum.

However, President Jair Bolsonaro on Friday said “political pressure” by India had postponed the flight. Serum chief Adar Poonawalla told the Times of India it would supply Brazil in two weeks.

India plans to offer 20 million doses to its neighbours, with the first batches shipped over the next two weeks, Bloomberg News reported. Latin America, Africa and ex-Soviet republics will be next.

Via AFP.

Related Posts

Leave a Reply

Your email address will not be published.